Cardioprotective effect of rutin considering cardiac enzyme level in induced myocardial infarction

The present study was designed to investigate effects of rutin on isoproterenol induced myocardial infarction (MI) by considering enzyme level in rats. Rats were treated with rutin contineously for 10 days (10 mg/kg/day, i.p.,); MI were induced by treating rats with isoproterenol for last 2 consecutive days (5.25 and 8 mg/kg, i.p). Protein kinase C (PKC), malonylaldehyde (MAL), Glutathione (GSH), superoxide dismutase (SOD) and survival rate were evaluated. Rutin enhanced survival rate evaluated at the end of experiment. Result shows significant decrease in level of PKC (P < 0.001) and MAL enzyme (P < 0.01) while elevation of GSH (P < 0.001) and SOD (P < 0.001) level in pretreated rutin + isoproterenol group and pretreated rutin group as compared to isoproterenol treated group indicates cardioprotective effect of rutin. The results indicate that Rutin significantly reduces myocardial infarction and emphasize the beneficial action in prevention of MI.Colegio de Farmacéuticos de la Provincia de Buenos Aire

Development of mucoadhesive in-situ nasal gel formulation for enhanced bioavailability and efficacy of rizatriptan in migraine treatment

This research article focuses on the development of an in-situ nasal gel formulation for the antimigraine agent, Rizatriptan (RZT), to enhance its bioavailability and efficacy in treating migraine. The aim of the study was to overcome the challenges of rapid mucociliary clearance. Carbopol 934P (1–2 %w/v) was added to the primary solution, followed by HPMC K4M (0.4–1.2 %w/v). Different copolymers were tested, and HPMC K4M was chosen due to its compatibility with the other ingredients. The pH of all formulations was in the nasal pH range, and the drug content was above 97% in all batches. Gelling time varied from 1.3 to 8.6 sec, with low gelling time observed when viscosity and mucoadhesive strength were high. The results were analyzed using a statistical model with interactive and polynomial terms. The statistical analysis showed a good correlation between dependent and independent variables, with R2 values of 0.97758 and 0.948931 for viscosity and mucoadhesive strength, respectively. The Cmax of RZT in the brain was significantly higher (p < 0.05) via intra-nasal (340.27 ng) route as compared to the oral route and the same was the case for AUC. Finally, it was concluded that the RZT nasal in-situ gel system improves bioavailability compared with oral route and could provide fast action in migraine therapy

Physician perceptions of pharmacologic treatment options for chorea associated with Huntington disease in the United States

<p><b>Objective:</b> To survey neurologists and obtain clinical perceptions of tetrabenazine for the treatment of chorea in patients with Huntington disease (HD).</p> <p><b>Methods:</b> Board-certified/board-eligible neurologists, in practice for ≥5 years, who had treated treat ≥3 HD patients in the past 2 years, were recruited from an online physician panel to participate in a cross-sectional, web-based survey. Respondents provided information about themselves, their practice, approaches to HD chorea management and perceptions of available treatments.</p> <p><b>Results:</b> Two hundred neurologists responded to the survey. Based on clinician responses, the most common reasons to treat chorea are impairment in activities of daily living (54%) and quality of life (41%). Although tetrabenazine was the only approved treatment for chorea in HD patients at the time of this analysis, it was only prescribed to ∼50% of patients with HD-related chorea. More than half of physicians perceive tetrabenazine as having minimal or no effectiveness in improving chorea. More than 40% of physicians consider tetrabenazine to be a non-optimal treatment, and 51% of physicians agree that they are unable to titrate to efficacious doses due to adverse side effects or tolerability concerns. Physicians report that side effects leading to dose interruptions (33%) and reductions (30%) occur in their patients “often” or “almost always”. The most common side effects that led to insufficient dosing and disruptions in titration were sedation and somnolence (41%), depression (24%) and anxiety (22%).</p> <p><b>Conclusions:</b> Many physicians who treat HD-related chorea report that tolerability issues with tetrabenazine impact their ability to effectively use tetrabenazine in their clinical practice.</p

Detection of high frequency of mutations in a breast and/or ovarian cancer cohort: implications of embracing a multi-gene panel in molecular diagnosis in India

Breast and/or ovarian cancer (BOC) are among the most frequently diagnosed forms of hereditary cancers and leading cause of death in India. This emphasizes on the need for a cost-effective method for early detection of these cancers. We sequenced 141 unrelated patients and families with BOC using the TruSight Cancer panel, which includes 13 genes strongly associated with risk of inherited BOC. Multi-gene sequencing was done on the Illumina MiSeq platform. Genetic variations were identified using the Strand NGS software and interpreted using the StrandOmics platform. We were able to detect pathogenic mutations in 51 (36.2%) cases, out of which 19 were novel mutations. When we considered familial breast cancer cases only, the detection rate increased to 52%. When cases were stratified based on age of diagnosis into three categories,. 40 years, 40-50 years and >50 years, the detection rates were higher in the first two categories (44.4% and 53.4%, respectively) as compared with the third category, in which it was 26.9%. Our study suggests that next-generation sequencing-based multi-gene panels increase the sensitivity of mutation detection and help in identifying patients with a high risk of developing cancer as compared with sequential tests of individual genes